

Date:01-11-2022

To,
Cooperate Relation Department
The BSE LIMITED

1st Floor, Phiroze leejeebhoy Towers,
Dalal Street,
Mumbai-400001

Script Code: 531210

Dear Sir/ Madam,

Sub: Newspaper clipping of the Un-Audited Financial Results pursuant to Regulation 47(3) of SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 for the Quarter and Half Year Ended on 30th September, 2022.

Please find enclosed herewith Newspaper clippings of Un-Audited Financial Results for the quarter and half year ended on 30th September, 2022 published in FREE PRESS JOURNAL and NAVSHAKTI on 1st November, 2022 in pursuance of Regulation 47(3) of SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015, which were approved in the Board meeting held on 31st October, 2022.

Kindly acknowledge the receipt of the same and update in your records.

Thanking you,

Yours faithfully,

For Colinz Laboratories Ltd.,

Dr. Mani L. S.

Director & Company Secreta

DIN: 00825886

Colinz Laboratories Limited

CIN NO- L24200MH1986PLC041128

e-ti wo De Sul Bid Su

Ter

Sul Pre Pac Pac Pac We

1 (A

B) 7

C) N D) E

PRO

* FREE PRESS JOURNAL *

THE FREE PRESS JOURNAL www.freepressjournal.in MUMBAI | TUESDAY | NOVEMBER 1, 2022

https://www.axisbank.com/auction-notices and/or https://axisbank.auctiontiger.net (Auction ID is mentioned above). Date: 01-11-2022 Place: Mumbai

Add: Office No. 119, 18t Hoot, Since Sidhivinayak Sankul, Oak Baug, Station Road, Kalyan (W), Dist. Thane.

COLINZ LABORATORIES LIMITED

A-101, Pratik Ind. Estate, Next to Fortis Hospital, Mulund-Goregaon Link Road, Mumbai – 400 078. (CIN NO : L24200MH1986PLC041128)

EXTRACTS OF UN-AUDITED RESULTS FOR THE QUARTER ENDED 30TH SEP, 2022

		1 5 95 006		A CHARLES AND A CHARLES			LULL
	Part of the same o			la a la la	The street	(Rs	. In "Lacs"
S. No.	PARTICULARS Revenue from Operations	QUARTER ENDED Un-Audited			HALF YEAR ENDED Un-Audited		YEAR ENDED Audited
		2	Net Profit/(Loca) for the section	196.16	187.93	197.97	387.15
	Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extraordinary Items).	16.66	14.28	13.61	90	That is	714.00
3	Net Profit/(Loss) for the period before Tax (after Exceptional and/or Extraordinary Items).	0.10			24.81	30.94	48.03
4	Net Profit/(Loss) for the period after Tax (after Exceptional and/or Extraordinary Items).	16.66	14.28	13.61	24.81	30.94	48.03
5	Total Comprehensive Income for the period	11.66	11.03	9.90	18.35	22.69	33.93
	and Other Comprehensive Income (Net of Tax).	21.71	4.98	1E 7E	20.00	Strings	5-125g - 1 2750 1152
6	Equity Share Capital (Face Value of Rs. 10/- each).	251.91		15.75	28.86	26.69	39.61
	Earning Per Share (Face value of Rs. 10/ cosh)	201.91	251.91	354.50	354.50	251.91	354.50
	(not annulised) (in Rs.) 1) Basic 2) Diluted	0.46	0.44	0.34	0.63	0.90	0.74
	The second secon	0.46	0.44	0.34	0.63	0.00	ARREST AND

The above is an extract of the detailed format of financial results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. The full format of the Financial Results is available on the website of BSE at www.bseindia.com and on the Company's website at www.findoc-cll.in.

The above financial results have been reviewed and recommended by the Audit Committee and approved by the Board of

3) Previous figures have been regrouped/rearranged, wherever necessary.

For and on behalf of the Board COLINZ LABORATORIES LTD. CIN NO: L24200MH1986PLC041128

Dr. MANI L. S.

(Director & Company Secretary) (DIN NO: 00825886)

31" October, 2022



* NAV SHAKTIX

१० नव शक्ति। मुंबई, मंगळवार, १ नोव्हेंबर २०२२

A-101, Pratik Ind. Estate, Next to Fortis Hospital, Mulund-Goregaon Link Road, Mumbal — 400 078. (CIN NO : L24200MH1986PLC041128)

AUDITED RESULTS FOR THE QUARTER ENDED 30TH SEP, 2022

S. No.	PARTICULARS	QUARTER ENDED Un-Audited			HALF YEAR ENDED Un-Audited		YEAR ENDED Audited
		1	Revenue from Operations	196.16	187.93	197.97	387.15
2	Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extraordinary Items).	16.66	14.28	13.61	24.81	30.94	48.03
3	Net Profit/(Loss) for the period before Tax (after Exceptional and/or Extraordinary Items).	16.66	14.28	13.61	24.81	30.94	48.03
4	Net Profit/(Loss) for the period after Tax (after Exceptional and/or Extraordinary Items).	11.66	11.03	9.90	18.35	22.69	33.93
5	Total Comprehensive Income for the period (Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income(Net of Tax).	21.71	4.98	15.75	28.86	26.69	39.61
6	Equity Share Capital (Face Value of Rs. 10/- each).	251.91	251.91	354.50	354.50	251.91	354.50
7	Earning Per Share (Face value of Rs. 10/- each) (not annulised) (in Rs.)		Y.	181 181 - 181 - 181 - 181 - 181 - 181 - 181 - 181 - 181 - 181 - 181 - 181 - 181 - 181 - 181 - 181 - 181 - 181 - 181	2,00	erg again	e a compensario
	1) Basic 2) Diluted	0.46 0.46	The Report of				1 1 1 1 1 1

- 1) The above is an extract of the detailed format of financial results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. The full format of the Financial Results is available on the website of BSE at www.bseindia.com and on the Company's website at www.findoc-cll.in.
- The above financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meetings held on 31st Oct, 2022.

For and on behalf of the Board COLINZ LABORATORIES LTD. CIN NO : L24200MH1986PLC041128

Dr. MANI L. S.

(Director & Company Secretary) (DIN NO: 00825886)

